These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29140059)

  • 1. Preemption of Non-Federal Restraints on Off-Label Product Communications.
    Chasnow J; Levitt G
    Food Drug Law J; 2016; 71(2):249-70. PubMed ID: 29140059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buckman extended: federal preemption of state fraud-on-the-FDA statutes.
    Gaddis CA
    Food Drug Law J; 2014; 69(1):113-36, iii. PubMed ID: 24772688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The next forum for unraveling FDA off-label marketing rules: State and federal legislatures.
    Sinha MS; Kesselheim AS
    PLoS Med; 2018 May; 15(5):e1002564. PubMed ID: 29738523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
    Thomadsen BR; Heaton HT; Jani SK; Masten JP; Napolitano ME; Ouhib Z; Reft CS; Rivard MJ; Robin TT; Subramanian M; Suleiman OH
    Med Phys; 2010 May; 37(5):2300-11. PubMed ID: 20527564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical devices; preemption of state product liability claims--FDA. Proposed rule.
    Fed Regist; 1997 Dec; 62(239):65384-8. PubMed ID: 10176832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-label marketing and the First Amendment.
    Boumil MM
    N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
    Wang B; Studdert DM; Sarpatwari A; Franklin JM; Landon J; Kesselheim AS
    PLoS One; 2017; 12(4):e0175313. PubMed ID: 28388667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preemption of the "fraud on the FDA" exception to Michigan's tort immunity statute for drug manufacturers: reconsidering Garcia and Desiano after Levine.
    Murdey J
    Food Drug Law J; 2011; 66(1):85-104, ii-iii. PubMed ID: 24505848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guide to preemption of state-law claims against Class III PMA medical devices.
    Whitney DW
    Food Drug Law J; 2010; 65(1):113-39, ii-iii. PubMed ID: 24475536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual regulatory pharmaceutical labeling schemes; the role of the Federal Preemption Doctrine.
    Fern FH; Bartell L
    Health Matrix; 1987; 5(3):17-23. PubMed ID: 10285381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States v. Caronia: Off-Label Drug Promotion and First Amendment Balancing.
    Rabinowitz DP
    Fordham Law Rev; 2018 Apr; 86(5):2595-623. PubMed ID: 29993225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA preemption of drug and device labeling: who should decide what goes on a drug label?
    Valoir T; Ghosh S
    Health Matrix Clevel; 2011; 21(2):555-98. PubMed ID: 22145525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
    Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
    Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of Wyeth v. Levine on FDA regulation of prescription drugs.
    Ausness RC
    Food Drug Law J; 2010; 65(2):247-83, i-ii. PubMed ID: 24475542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases.
    Liu S; Mello MM; Kesselheim AS
    J Health Polit Policy Law; 2021 Jun; 46(3):487-504. PubMed ID: 33647951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Origins of the prohibition against off-label promotion.
    Coleman TS
    Food Drug Law J; 2014; 69(2):161-236, i. PubMed ID: 25163210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 19. Exemption from federal preemption of state and local cigarette and smokeless tobacco requirements; revocation. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66636. PubMed ID: 11503697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-label use of medical devices in radiology: regulatory standards and recent developments.
    Smith JJ
    J Am Coll Radiol; 2010; 7(2):115-9. PubMed ID: 20142085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.